ID

36884

Description

PROSTAC: Multicentre Biomarker Study in CRPC Treated With Chemotherapy; ODM derived from: https://clinicaltrials.gov/show/NCT02362620

Lien

https://clinicaltrials.gov/show/NCT02362620

Mots-clés

Versions (1)
  1. 18/06/2019 18/06/2019 -
Détendeur de droits

See clinicaltrials.gov

Téléchargé le

18 juin 2019

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY 4.0
Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Retour au modèle Commentaires
Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Eligibility Prostate Cancer NCT02362620

Anglais

Eligibility Prostate Cancer NCT02362620

1 Formulaires  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
1. provision of informed consent.
Description

Informed Consent

Type de données

boolean

Alias
UMLS CUI [1]
C0021430
2. eighteen years of age or older.
Description

Age

Type de données

boolean

Alias
UMLS CUI [1]
C0001779
3. general health status acceptable and compatible with active treatment: ecog ≤0-2.
Description

Health Status Acceptable | Health Status Compatible with Therapeutic procedure | ECOG performance status

Type de données

boolean

Alias
UMLS CUI [1,1]
C0018759
UMLS CUI [1,2]
C1879533
UMLS CUI [2,1]
C0018759
UMLS CUI [2,2]
C0332290
UMLS CUI [2,3]
C0087111
UMLS CUI [3]
C1520224
4. histological confirmation of prostate cancer diagnosis.
Description

Prostate carcinoma

Type de données

boolean

Alias
UMLS CUI [1]
C0600139
5. prior resistance to biochemical castration with an lhrh agonist (or surgical castration through bilateral orchiectomy) and progression to an anti-androgen drug (e.g. bicalutamide, nilutamide or cyproterone acetate).
Description

Resistant to Chemical male castration | Resistant to LHRH Agonist | Resistant to Male Castration | Androgen Antagonists | bicalutamide | nilutamide | Cyproterone Acetate

Type de données

boolean

Alias
UMLS CUI [1,1]
C0332325
UMLS CUI [1,2]
C0455189
UMLS CUI [2,1]
C0332325
UMLS CUI [2,2]
C1518041
UMLS CUI [3,1]
C0332325
UMLS CUI [3,2]
C0007347
UMLS CUI [4]
C0002842
UMLS CUI [5]
C0285590
UMLS CUI [6]
C0068771
UMLS CUI [7]
C0056855
6. biochemical progression upon prior treatment in agreement with psawg2 criteria, confirmed by a second psa test.
Description

Prior Therapy | Disease Progression Biochemical

Type de données

boolean

Alias
UMLS CUI [1]
C1514463
UMLS CUI [2,1]
C0242656
UMLS CUI [2,2]
C0205474
7. castrate levels of testosterone in peripheral blood: testosterone <0.5 ng/ml.
Description

Castration Levels of Testosterone Peripheral blood | Testosterone measurement

Type de données

boolean

Alias
UMLS CUI [1,1]
C4289828
UMLS CUI [1,2]
C0229664
UMLS CUI [2]
C0523912
8. candidates for standard treatment with:
Description

Patients Appropriate Standard therapy

Type de données

boolean

Alias
UMLS CUI [1,1]
C0030705
UMLS CUI [1,2]
C1548787
UMLS CUI [1,3]
C2936643
1. docetaxel (75 mg/m2 every three weeks) plus prednisone (5 mg/12 h). or
Description

Docetaxel Dose Frequency | Prednisone Dose /12h

Type de données

boolean

Alias
UMLS CUI [1,1]
C0246415
UMLS CUI [1,2]
C0178602
UMLS CUI [1,3]
C0439603
UMLS CUI [2,1]
C0032952
UMLS CUI [2,2]
C0178602
UMLS CUI [2,3]
C0456695
2. cabazitaxel (20 or 25 mg/m2 every three weeks) plus prednisone (5 mg/12 h).
Description

Cabazitaxel Dose Frequency | Prednisone Dose /12h

Type de données

boolean

Alias
UMLS CUI [1,1]
C2830183
UMLS CUI [1,2]
C0178602
UMLS CUI [1,3]
C0439603
UMLS CUI [2,1]
C0032952
UMLS CUI [2,2]
C0178602
UMLS CUI [2,3]
C0456695
9. availability of anatomopathological tumour material (e.g. a paraffin block of the prostatectomy or initial biopsy of the metastasis).
Description

Availability of Paraffin Embedded Tissue Prostatectomy | Paraffin Embedded Tissue Biopsy Neoplasm Metastasis

Type de données

boolean

Alias
UMLS CUI [1,1]
C0470187
UMLS CUI [1,2]
C1519524
UMLS CUI [1,3]
C0033573
UMLS CUI [2,1]
C1519524
UMLS CUI [2,2]
C0005558
UMLS CUI [2,3]
C0027627
10. acceptable hematological, hepatic and renal functions and without contraindications for the administration of docetaxel or cabaziatxel in agreement with its respective summary of products characteristics.
Description

Hematologic function | Liver function | Renal function | Medical contraindication Absent Docetaxel | Medical contraindication Absent Cabazitaxel

Type de données

boolean

Alias
UMLS CUI [1]
C0221130
UMLS CUI [2]
C0232741
UMLS CUI [3]
C0232804
UMLS CUI [4,1]
C1301624
UMLS CUI [4,2]
C0332197
UMLS CUI [4,3]
C0246415
UMLS CUI [5,1]
C1301624
UMLS CUI [5,2]
C0332197
UMLS CUI [5,3]
C2830183
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
1. previous cancer diagnosis, except those patients who had a localized malignant tumour and who are five years cancer-free, as well as subjects with a history of skin cancers (of non-melanoma type) or excised in situ carcinomas.
Description

Malignant Neoplasms | Exception Malignant Neoplasm Localized | Exception Malignant Neoplasm Free of | Exception Skin carcinoma | Exception Carcinoma in Situ Resected

Type de données

boolean

Alias
UMLS CUI [1]
C0006826
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0006826
UMLS CUI [2,3]
C0392752
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C0006826
UMLS CUI [3,3]
C0332296
UMLS CUI [4,1]
C1705847
UMLS CUI [4,2]
C0699893
UMLS CUI [5,1]
C1705847
UMLS CUI [5,2]
C0007099
UMLS CUI [5,3]
C1521996
2. medical histories, be they psychiatric or of any other character, which, according to the judgement of the investigator, might interfere with the subject's granting of informed consent or the safe execution of the procedures required in the study.
Description

Medical History Interferes with Informed Consent | Medical History Interferes with Protocol Compliance

Type de données

boolean

Alias
UMLS CUI [1,1]
C0262926
UMLS CUI [1,2]
C0521102
UMLS CUI [1,3]
C0021430
UMLS CUI [2,1]
C0262926
UMLS CUI [2,2]
C0521102
UMLS CUI [2,3]
C0525058
Retour au début de la page

Similar models

Eligibility Prostate Cancer NCT02362620

1 Formulaires
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
C1512693 (UMLS CUI)
Informed Consent
Item
1. provision of informed consent.
boolean
C0021430 (UMLS CUI [1])
Age
Item
2. eighteen years of age or older.
boolean
C0001779 (UMLS CUI [1])
Health Status Acceptable | Health Status Compatible with Therapeutic procedure | ECOG performance status
Item
3. general health status acceptable and compatible with active treatment: ecog ≤0-2.
boolean
C0018759 (UMLS CUI [1,1])
C1879533 (UMLS CUI [1,2])
C0018759 (UMLS CUI [2,1])
C0332290 (UMLS CUI [2,2])
C0087111 (UMLS CUI [2,3])
C1520224 (UMLS CUI [3])
Prostate carcinoma
Item
4. histological confirmation of prostate cancer diagnosis.
boolean
C0600139 (UMLS CUI [1])
Resistant to Chemical male castration | Resistant to LHRH Agonist | Resistant to Male Castration | Androgen Antagonists | bicalutamide | nilutamide | Cyproterone Acetate
Item
5. prior resistance to biochemical castration with an lhrh agonist (or surgical castration through bilateral orchiectomy) and progression to an anti-androgen drug (e.g. bicalutamide, nilutamide or cyproterone acetate).
boolean
C0332325 (UMLS CUI [1,1])
C0455189 (UMLS CUI [1,2])
C0332325 (UMLS CUI [2,1])
C1518041 (UMLS CUI [2,2])
C0332325 (UMLS CUI [3,1])
C0007347 (UMLS CUI [3,2])
C0002842 (UMLS CUI [4])
C0285590 (UMLS CUI [5])
C0068771 (UMLS CUI [6])
C0056855 (UMLS CUI [7])
Prior Therapy | Disease Progression Biochemical
Item
6. biochemical progression upon prior treatment in agreement with psawg2 criteria, confirmed by a second psa test.
boolean
C1514463 (UMLS CUI [1])
C0242656 (UMLS CUI [2,1])
C0205474 (UMLS CUI [2,2])
Castration Levels of Testosterone Peripheral blood | Testosterone measurement
Item
7. castrate levels of testosterone in peripheral blood: testosterone <0.5 ng/ml.
boolean
C4289828 (UMLS CUI [1,1])
C0229664 (UMLS CUI [1,2])
C0523912 (UMLS CUI [2])
Patients Appropriate Standard therapy
Item
8. candidates for standard treatment with:
boolean
C0030705 (UMLS CUI [1,1])
C1548787 (UMLS CUI [1,2])
C2936643 (UMLS CUI [1,3])
Docetaxel Dose Frequency | Prednisone Dose /12h
Item
1. docetaxel (75 mg/m2 every three weeks) plus prednisone (5 mg/12 h). or
boolean
C0246415 (UMLS CUI [1,1])
C0178602 (UMLS CUI [1,2])
C0439603 (UMLS CUI [1,3])
C0032952 (UMLS CUI [2,1])
C0178602 (UMLS CUI [2,2])
C0456695 (UMLS CUI [2,3])
Cabazitaxel Dose Frequency | Prednisone Dose /12h
Item
2. cabazitaxel (20 or 25 mg/m2 every three weeks) plus prednisone (5 mg/12 h).
boolean
C2830183 (UMLS CUI [1,1])
C0178602 (UMLS CUI [1,2])
C0439603 (UMLS CUI [1,3])
C0032952 (UMLS CUI [2,1])
C0178602 (UMLS CUI [2,2])
C0456695 (UMLS CUI [2,3])
Availability of Paraffin Embedded Tissue Prostatectomy | Paraffin Embedded Tissue Biopsy Neoplasm Metastasis
Item
9. availability of anatomopathological tumour material (e.g. a paraffin block of the prostatectomy or initial biopsy of the metastasis).
boolean
C0470187 (UMLS CUI [1,1])
C1519524 (UMLS CUI [1,2])
C0033573 (UMLS CUI [1,3])
C1519524 (UMLS CUI [2,1])
C0005558 (UMLS CUI [2,2])
C0027627 (UMLS CUI [2,3])
Hematologic function | Liver function | Renal function | Medical contraindication Absent Docetaxel | Medical contraindication Absent Cabazitaxel
Item
10. acceptable hematological, hepatic and renal functions and without contraindications for the administration of docetaxel or cabaziatxel in agreement with its respective summary of products characteristics.
boolean
C0221130 (UMLS CUI [1])
C0232741 (UMLS CUI [2])
C0232804 (UMLS CUI [3])
C1301624 (UMLS CUI [4,1])
C0332197 (UMLS CUI [4,2])
C0246415 (UMLS CUI [4,3])
C1301624 (UMLS CUI [5,1])
C0332197 (UMLS CUI [5,2])
C2830183 (UMLS CUI [5,3])
Item Group
C0680251 (UMLS CUI)
Malignant Neoplasms | Exception Malignant Neoplasm Localized | Exception Malignant Neoplasm Free of | Exception Skin carcinoma | Exception Carcinoma in Situ Resected
Item
1. previous cancer diagnosis, except those patients who had a localized malignant tumour and who are five years cancer-free, as well as subjects with a history of skin cancers (of non-melanoma type) or excised in situ carcinomas.
boolean
C0006826 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0006826 (UMLS CUI [2,2])
C0392752 (UMLS CUI [2,3])
C1705847 (UMLS CUI [3,1])
C0006826 (UMLS CUI [3,2])
C0332296 (UMLS CUI [3,3])
C1705847 (UMLS CUI [4,1])
C0699893 (UMLS CUI [4,2])
C1705847 (UMLS CUI [5,1])
C0007099 (UMLS CUI [5,2])
C1521996 (UMLS CUI [5,3])
Medical History Interferes with Informed Consent | Medical History Interferes with Protocol Compliance
Item
2. medical histories, be they psychiatric or of any other character, which, according to the judgement of the investigator, might interfere with the subject's granting of informed consent or the safe execution of the procedures required in the study.
boolean
C0262926 (UMLS CUI [1,1])
C0521102 (UMLS CUI [1,2])
C0021430 (UMLS CUI [1,3])
C0262926 (UMLS CUI [2,1])
C0521102 (UMLS CUI [2,2])
C0525058 (UMLS CUI [2,3])
Retour au début de la page 

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial